Convergent Science Physical Oncology (CSPO) has named Professor Robert Ivkov, from Johns Hopkins University School of Medicine, Maryland, USA as its new Editor-in-Chief.
As Associate Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins, Professor Ivkov’s research encompasses physics, biology, chemistry, and engineering, making him ideally placed to lead a journal that highlights the convergence of different disciplines to tackle cancer.
Professor Ivkov said: “I was delighted to receive the invitation from IOP Publishing, and I accepted the position of EIC because I believe CSPO provides a timely and relevant forum for disseminating advances arising from developing fields.
“I hope to see the journal develop into the leading and best-recognised publication that defines and drives physical oncology. I hope to see it evolve a recognised author and reader base; grow the Editorial Board; and expand participation from a wider community practicing clinicians and medical physicists as well as physicists, biologists, and engineers.
“I also hope to see the journal develop as a platform, with its Board, readers, and contributing authors becoming a recognised voice to define and shape the developing field of convergent science in physical oncology.”
Richard Kelsall, publisher for CSPO, said: “We are extremely grateful to Professor Ivkov for agreeing to take on the role of Editor-in-Chief, and we are looking forward to working closely with him to build and develop his vision for CSPO.”
Professor Ivkov added: “This is a significant time for the field, and the journal. There is a growing recognition that convergent science – the convergence of physics, biology, and engineering with clinical practice – is a necessary evolution to address the complexities of cancer.
“Specifically, in the field of physical oncology the most exciting stand-outs are advances in cancer immunology, and discoveries that energy-based therapies (ionizing radiation and heat) have immune stimulating potential that can be exploited to treat metastatic disease.”
Professor Ivkov’s scientific background is in physical chemistry (M.Sc., University of Toronto; and, Ph.D. University of Maryland, College Park) with both theoretical and experimental focus encompassing statistical mechanics, thermodynamics, and critical phenomena. His Ph.D. research characterised the reversible polymerisation of muscle actin as a temperature-dependent higher-order phase transition, using small angle neutron scattering to measure the degree of polymerisation.
Following his Ph.D., he was awarded a National Research Council post-doctoral fellowship at the National Institute of Standards and Technology (NIST, Gaithersburg, MD) where he continued to study the properties of polymer, dendrimer, clay-polymer, and other complex solutions and suspensions.
He co-founded a start-up biotechnology company and worked for many years developing antibody-labelled magnetic iron oxide nanoparticles as a thermal ablation tool for breast cancer. In early 2008, the company underwent a merger, and he joined the faculty at the Johns Hopkins University School of Medicine.
His current research focuses specifically on the development and characterisation of magnetic nanostructured materials and devices for cancer therapy; and, most recently on how these interact with the complex biology and immunology of cancer.
The full interview with Professor Ivkov is available on IOPscience.